Daxor (DXR) Competitors $8.75 -0.04 (-0.46%) As of 03:58 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock DXR vs. PROF, AVR, LNSR, RCEL, PDEX, LUCD, KRMD, LUNG, INFU, and OBIOShould you be buying Daxor stock or one of its competitors? The main competitors of Daxor include Profound Medical (PROF), Anteris Technologies Global (AVR), LENSAR (LNSR), AVITA Medical (RCEL), Pro-Dex (PDEX), Lucid Diagnostics (LUCD), KORU Medical Systems (KRMD), Pulmonx (LUNG), InfuSystem (INFU), and Orchestra BioMed (OBIO). These companies are all part of the "medical equipment" industry. Daxor vs. Its Competitors Profound Medical Anteris Technologies Global LENSAR AVITA Medical Pro-Dex Lucid Diagnostics KORU Medical Systems Pulmonx InfuSystem Orchestra BioMed Daxor (NASDAQ:DXR) and Profound Medical (NASDAQ:PROF) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, community ranking, risk, dividends, earnings, valuation, media sentiment, profitability and analyst recommendations. Which has preferable valuation and earnings, DXR or PROF? Daxor has higher earnings, but lower revenue than Profound Medical. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDaxor$2.13M19.86N/AN/AN/AProfound Medical$11.86M16.57-$28.57M-$1.22-5.36 Does the MarketBeat Community believe in DXR or PROF? Profound Medical received 39 more outperform votes than Daxor when rated by MarketBeat users. However, 100.00% of users gave Daxor an outperform vote while only 69.49% of users gave Profound Medical an outperform vote. CompanyUnderperformOutperformDaxorOutperform Votes2100.00% Underperform VotesNo VotesProfound MedicalOutperform Votes4169.49% Underperform Votes1830.51% Do analysts rate DXR or PROF? Daxor currently has a consensus target price of $25.00, suggesting a potential upside of 185.71%. Profound Medical has a consensus target price of $11.50, suggesting a potential upside of 75.84%. Given Daxor's higher possible upside, equities analysts clearly believe Daxor is more favorable than Profound Medical.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Daxor 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Profound Medical 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer DXR or PROF? In the previous week, Profound Medical had 1 more articles in the media than Daxor. MarketBeat recorded 2 mentions for Profound Medical and 1 mentions for Daxor. Daxor's average media sentiment score of 1.87 beat Profound Medical's score of 1.22 indicating that Daxor is being referred to more favorably in the media. Company Overall Sentiment Daxor Very Positive Profound Medical Positive Which has more volatility & risk, DXR or PROF? Daxor has a beta of -0.13, indicating that its share price is 113% less volatile than the S&P 500. Comparatively, Profound Medical has a beta of 0.48, indicating that its share price is 52% less volatile than the S&P 500. Is DXR or PROF more profitable? Daxor has a net margin of 0.00% compared to Profound Medical's net margin of -349.41%. Daxor's return on equity of 0.00% beat Profound Medical's return on equity.Company Net Margins Return on Equity Return on Assets DaxorN/A N/A N/A Profound Medical -349.41%-85.22%-64.87% Do insiders & institutionals have more ownership in DXR or PROF? 1.3% of Daxor shares are held by institutional investors. Comparatively, 47.9% of Profound Medical shares are held by institutional investors. 59.0% of Daxor shares are held by company insiders. Comparatively, 1.5% of Profound Medical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. SummaryDaxor beats Profound Medical on 8 of the 14 factors compared between the two stocks. Get Daxor News Delivered to You Automatically Sign up to receive the latest news and ratings for DXR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DXR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DXR vs. The Competition Export to ExcelMetricDaxorSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$42.32M$4.32B$5.56B$8.50BDividend YieldN/A42.67%5.28%4.16%P/E RatioN/A27.8226.6419.64Price / Sales19.8668.18407.99152.17Price / CashN/A51.0838.2534.64Price / BookN/A5.746.974.60Net IncomeN/A$66.95M$3.23B$248.06M7 Day Performance-5.41%-2.95%-0.98%-1.03%1 Month Performance21.53%14.68%7.70%3.50%1 Year Performance-1.13%17.75%31.32%12.68% Daxor Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DXRDaxor3.961 of 5 stars$8.75-0.5%$25.00+185.7%-0.1%$42.32M$2.13M0.0037Positive NewsGap DownPROFProfound Medical2.5619 of 5 stars$5.48-0.2%$11.50+109.9%-30.7%$164.69M$11.86M-4.09150Positive NewsAVRAnteris Technologies GlobalN/A$4.47-3.5%$16.50+269.1%N/A$161.20M$2.71M0.00138Positive NewsLockup ExpirationAnalyst RevisionLNSRLENSAR1.4015 of 5 stars$13.54+0.1%$15.00+10.8%+156.1%$159.66M$57.07M-9.27110Positive NewsRCELAVITA Medical1.3488 of 5 stars$5.86-3.0%$17.25+194.4%-34.5%$154.91M$71.66M-2.45130Analyst RevisionPDEXPro-Dex3.2152 of 5 stars$42.78+9.0%$56.00+30.9%+107.7%$139.51M$64.12M21.28140LUCDLucid Diagnostics3.5425 of 5 stars$1.26+1.2%$3.50+177.8%+74.9%$136.32M$4.17M-1.1170Short Interest ↓KRMDKORU Medical Systems3.3197 of 5 stars$2.84+1.8%$4.50+58.5%+36.2%$131.04M$35.08M-11.3680LUNGPulmonx3.8078 of 5 stars$3.18+1.6%$11.59+264.6%-53.8%$128.02M$87.47M-2.21250INFUInfuSystem2.3833 of 5 stars$6.06+6.7%$13.00+114.5%N/A$127.36M$137.58M101.02410News CoveragePositive NewsShort Interest ↑OBIOOrchestra BioMed3.053 of 5 stars$3.24+2.5%$14.20+338.3%-60.2%$124.13M$2.89M-2.014Positive News Related Companies and Tools Related Companies Profound Medical Alternatives Anteris Technologies Global Alternatives LENSAR Alternatives AVITA Medical Alternatives Pro-Dex Alternatives Lucid Diagnostics Alternatives KORU Medical Systems Alternatives Pulmonx Alternatives InfuSystem Alternatives Orchestra BioMed Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DXR) was last updated on 6/13/2025 by MarketBeat.com Staff From Our PartnersElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredWe’ve Entered the Most Bullish Phase of the CycleIt happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredCollect $7k per month from Tesla’s SECRET dividendI just uncovered a strategy that could pay out up to $7,013 every month—without needing a traditional dividend...Investors Alley | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Daxor Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Daxor With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
